Tempest Therapeutics (TPST) Stock Overview
A clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TPST Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Tempest Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.86 |
| 52 Week High | US$12.23 |
| 52 Week Low | US$1.50 |
| Beta | -1.68 |
| 1 Month Change | -4.12% |
| 3 Month Change | -23.46% |
| 1 Year Change | -70.45% |
| 3 Year Change | -93.15% |
| 5 Year Change | n/a |
| Change since IPO | -98.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| TPST | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | -3.0% | -0.3% |
| 1Y | -70.5% | 32.9% | 26.7% |
Return vs Industry: TPST underperformed the US Biotechs industry which returned 28.1% over the past year.
Return vs Market: TPST underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| TPST volatility | |
|---|---|
| TPST Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TPST's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TPST's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Matt Angel | www.tempesttx.com |
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd.
Tempest Therapeutics, Inc. Fundamentals Summary
| TPST fundamental statistics | |
|---|---|
| Market cap | US$25.53m |
| Earnings (TTM) | -US$43.10m |
| Revenue (TTM) | n/a |
Is TPST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TPST income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.10m |
| Earnings | -US$43.10m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TPST perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 05:39 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tempest Therapeutics, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Maurice Raycroft | Jefferies LLC |
| Aydin Huseynov | Ladenburg Thalmann & Company |